Intravenous immunoglobulin (IVIG) administration in sepsis has been surrounded with controversies since the publication of the first international consensus meeting on this potential therapy almost 40 years ago 1 . Researchers called for evaluation of different treatment doses and durations of IVIG treatment in sepsis, when one of the earliest randomised controlled trials (RCTs) showed no effect and higher rate of significant complications in the IVIG group, using 150 mg/kg bolus dose for three consecutive days 2 .Recent clinical trials used a wide variety of dosing regimes ranging from 200 mg/kg/day to 1000 mg/kg/day, with similarly disappointing results 3-5 . The study presented in the current